Proteintech Introduces Able AI to Streamline Antibody Selection and Experimental Design for Scientists

Proteintech Launches Able AI to Streamline Antibody Selection and Experiment Design

Proteintech, a recognized leader in antibodies and life science solutions, has introduced Able AI, an innovative artificial intelligence tool accessible now at ptglab.com/able. Able AI is engineered to assist scientists in selecting the most appropriate antibodies for their research and offers comprehensive guidance on experimental protocols.

Choosing the right antibody from an extensive range of options can be time-consuming and complex. Able AI addresses this challenge by analyzing research requirements and delivering precise product recommendations along with relevant scientific data. This reduces the effort spent on planning and product evaluation, allowing researchers to allocate more time to their core scientific work.

Building on Previous Innovations

This launch follows Proteintech's earlier introduction of 3D Epitope Mapping, which combines experimental data with AI-driven modeling to help scientists visualize antibody binding sites. That technology minimizes trial-and-error in experimental design, improving precision in product development.

According to Dr. Jason Li, CEO of Proteintech, “Able delivers product recommendations and experimental design support, enabling researchers to concentrate on advancing their discoveries. Our goal is to provide better science tools and service for every customer.”

Key Benefits of Able AI

• Pinpoints the ideal antibody based on specific research needs
• Offers detailed scientific information and product data
• Provides step-by-step guidance for experimental procedures
• Reduces time spent on product selection and experimental planning
• Available immediately and free to use

Scientists interested in using Able AI can access it directly at ptglab.com/able. This tool exemplifies how AI can support research efficiency by simplifying complex decision-making processes.

About Proteintech

Founded in 2001, Proteintech Group Inc. manufactures antibodies, proteins, nanobodies, and immunoassays. With the largest proprietary portfolio of self-manufactured antibodies covering approximately two-thirds of the human proteome, Proteintech offers over 300,000 cited products across various research fields.

The company also produces human-expressed cytokines, growth factors, and cGMP-grade bioactive proteins. Proteintech's facilities hold ISO13485 and ISO9001 certifications, underscoring their commitment to quality and reliability. For more information, visit ptglab.com.